<DOC>
	<DOCNO>NCT01807026</DOCNO>
	<brief_summary>This study do follow reason : To determine safety LY2886721 side effect may associate see much study drug blood cerebrospinal fluid one dose give healthy participant participant diagnose Alzheimer 's disease . It also look safe tolerable study drug give healthy participant higher dos . This research study conduct three group , refer Groups ( Cohorts ) A , B C. Group A enroll participant Alzheimer 's disease Groups B C enroll healthy participant . For Group A B , participation research study could last 34 day . For Group C , participation could last 60 day .</brief_summary>
	<brief_title>A Study LY2886721 Healthy Participants Participants Diagnosed With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy participant body mass index ( BMI ) 19 32 kilogram per square meter ( kg/m^2 ) , inclusive , screen . There restriction BMI participant diagnose AD Healthy participant take concomitant medication . For participant AD , concomitant medication determine investigator consultation Lilly clinical pharmacologist individual basis Cohort A : Participants define otherwise healthy male female determine medical history , physical examination diagnosis AD must least 45 year age Meets National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable AD ; determine clinician approve sponsor designee Mini Mental State Examination ( MMSE ) score 16 28 screening Modified Hachinski Ischemia Scale ( MHIS ) score &lt; 4 Capable understand signing informed consent , opinion investigator , participant Legally Authorized Representative ( LAR ) LAR must capable understand sign assent form participant may may sign informed consent , determine investigator . If receiving concurrent treatment acetylcholinesterase inhibitor ( AChEI ) and/or memantine , stable dose least 4 week Day 1 . Dosing must remain stable throughout study . Note : If participant recently stop ACHEIs and/or memantine , must discontinue treatment least 4 week Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>